PDA

View Full Version : SLNO (MC $24 M) Rare Disease in Phase 3 a Potential Blockbuster =MASSIVE Undervalued



AdriennHar
12-08-2017,
Soleno (SLNO) is a new formed company through the merger between Capnia and the private Essentials (merger completed in march 2017) thats why its still undiscovered. SLNO has a potential Blockbuster in Phase 3 for the treatment of Prader Willi Syndrome a Rare Disease for which there is no approved treatments . This unknown low float stock which has a terrible low valuation of $24 million could be the next SRPT the stock should be valued way over $100+ million right now for their Phase 3 Program and in the Billion if the outcome of the Phase 3 trial is positive which expected by next year .MYOK and SRPT both rare disease companies hitting Billion Dollar Valuation after Phase 2 results in just 10 patients , you will not find a rare disease company below $100 million valuation with a potential blockbuster in phase 3 that shows how terrible undervalued this stock is .GL

aeqyjhjr31
12-09-2017,
Once we break the MA (200) at 0.69 then $1+ coming quickly .
https://stockcharts.com/c-sc/sc?s=slno&p=D&yr=0&mn=9&dy=0&i=p93834726544&r=3658